GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (NAS:GILD) » Definitions » Cyclically Adjusted PB Ratio

Gilead Sciences (Gilead Sciences) Cyclically Adjusted PB Ratio : 3.71 (As of Apr. 27, 2024)


View and export this data going back to 1992. Start your Free Trial

What is Gilead Sciences Cyclically Adjusted PB Ratio?

As of today (2024-04-27), Gilead Sciences's current share price is $65.42. Gilead Sciences's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $17.65. Gilead Sciences's Cyclically Adjusted PB Ratio for today is 3.71.

The historical rank and industry rank for Gilead Sciences's Cyclically Adjusted PB Ratio or its related term are showing as below:

GILD' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 3.7   Med: 7.73   Max: 28.67
Current: 3.7

During the past years, Gilead Sciences's highest Cyclically Adjusted PB Ratio was 28.67. The lowest was 3.70. And the median was 7.73.

GILD's Cyclically Adjusted PB Ratio is ranked worse than
76.51% of 647 companies
in the Drug Manufacturers industry
Industry Median: 1.75 vs GILD: 3.70

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Gilead Sciences's adjusted book value per share data for the three months ended in Dec. 2023 was $18.324. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $17.65 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Gilead Sciences Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Gilead Sciences's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences Cyclically Adjusted PB Ratio Chart

Gilead Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.83 4.71 5.04 5.27 4.59

Gilead Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.27 4.95 4.50 4.28 4.59

Competitive Comparison of Gilead Sciences's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - General subindustry, Gilead Sciences's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gilead Sciences's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Gilead Sciences's Cyclically Adjusted PB Ratio falls into.



Gilead Sciences Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Gilead Sciences's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=65.42/17.65
=3.71

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gilead Sciences's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Gilead Sciences's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=18.324/129.4194*129.4194
=18.324

Current CPI (Dec. 2023) = 129.4194.

Gilead Sciences Quarterly Data

Book Value per Share CPI Adj_Book
201403 8.706 99.695 11.302
201406 10.544 100.560 13.570
201409 8.963 100.428 11.550
201412 10.291 99.070 13.444
201503 11.632 99.621 15.111
201506 11.057 100.684 14.213
201509 12.018 100.392 15.493
201512 13.034 99.792 16.904
201603 9.939 100.470 12.803
201606 11.672 101.688 14.855
201609 12.759 101.861 16.211
201612 14.418 101.863 18.318
201703 15.640 102.862 19.678
201706 17.364 103.349 21.744
201709 19.009 104.136 23.624
201712 15.628 104.011 19.446
201803 15.839 105.290 19.469
201806 16.722 106.317 20.356
201809 17.667 106.507 21.468
201812 16.683 105.998 20.369
201903 17.230 107.251 20.791
201906 17.858 108.070 21.386
201909 16.275 108.329 19.443
201912 17.792 108.420 21.238
202003 17.597 108.902 20.912
202006 14.376 108.767 17.106
202009 13.923 109.815 16.409
202012 14.515 109.897 17.094
202103 15.113 111.754 17.502
202106 15.712 114.631 17.739
202109 17.108 115.734 19.131
202112 16.801 117.630 18.485
202203 15.878 121.301 16.941
202206 16.137 125.017 16.705
202209 16.811 125.227 17.374
202212 17.033 125.222 17.604
202303 16.825 127.348 17.099
202306 16.966 128.729 17.057
202309 17.893 129.860 17.832
202312 18.324 129.419 18.324

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Gilead Sciences  (NAS:GILD) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Gilead Sciences Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Gilead Sciences's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Gilead Sciences (Gilead Sciences) Business Description

Address
333 Lakeside Drive, Foster, CA, USA, 94404
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Executives
Andrew D Dickinson officer: EVP, Chief Financial Officer 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Johanna Mercier officer: Chief Commercial Officer 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Merdad Parsey officer: Chief Medical Officer 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Sandra Patterson officer: SVP, Controllership 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Diane E. Wilfong officer: SVP, Controller & CAO 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Deborah H Telman officer: EVP, Corporate Affairs & GC 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Brett A Pletcher officer: EVP, Gen Counsel & Corp Sec 333 LAKESIDE DRIVE, FOSTER CITY X1 94404
Jeffrey Bluestone director C/O PROVENTION BIO, INC., P.O. BOX 666, OLDWICK NJ 08858
Anthony Welters director
Javier Rodriguez director 601 HAWAII ST., EL SEGUNDO CA 90245
John Francis Cogan director 2010 NORTH FIRST STREET, SUITE 310, SAN JOSE CA 95131
Gayle E Wilson director C/O GILEAD SCIENCES, INC., 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Olsen Per Wold director C/O GILEAD SCIENCES, 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Sandra Horning director 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Richard James Whitley director UAB, CHB 303, 1600 7TH AVENUE SOUTH, BIRMINGHAM AL 35233-1711